AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8311488
Drug: KW-2307 single
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 single administration
Trial: 8311488
Drug: KW-2307 repeated
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 repeated administration
Trial: 25363835
Drug: AQW051, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AQW051, administered over a broad dose range (up to 200 mg single dose, 75 mg multiple daily doses)
Trial: 2892991
Drug: Topical interferon‐beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon‐beta (IFN‐beta) gel (10(5) U/g) 4 times daily applied locally during eruptions (about 10 days)
Trial: 30566636
Drug: 4 ID
RxNorm normalized name: Seequin 4 IDS 4 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ID PEP booster doses of 0.1 mL PCEV
Trial: 30566636
Drug: 2 ID
RxNorm normalized name: Seequin 2 IDS 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ID PEP booster doses of 0.1 mL PCEV
Trial: 30566636
Drug: Primary vaccination
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary vaccination with 2 ID doses of 0.1 mL PCEV
Trial: 26782228
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of BioPQQ™ per day for 12 weeks
Trial: 21155437
Drug: Rocuronium group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium group (n = 30) received PB with a local anesthetic mixture (Lidocaine 2% + Bupivacaine 0.5%) to which was added 0.06 mg/Kg of rocuronium
Trial: 17289893
Drug: PV701 (24x10(9)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PV701 (24x10(9) plaque‐forming units/m2 for the first dose, 120x10(9) plaque‐forming units/m2 for doses 2 to 6)
Trial: 16332657
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium (1259 +/- 9 mg/d), high dairy (high/high)
Trial: 16332657
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium (1259 +/- 9 mg/d), low dairy (high/low)
Trial: 16332657
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium (349 +/- 8 mg/d), low dairy (low/low)
Trial: 11959610
Drug: Azithromycin 10
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 10 mg/kg for 3 days
Trial: 11959610
Drug: Azithromycin 20
RxNorm normalized name: azithromycin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 20 mg/kg for 3 days
Trial: 6938019
Drug: estracyt or
RxNorm normalized name: Estracyt Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estracyt or vincristine alone or in combination
Trial: 31366352
Drug: Cashew apple
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cashew apple juice (CAJ) at 3.5 mL/kgBM/day for 4 weeks
Trial: 27534738
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg once daily for 12 weeks
Trial: 27534738
Drug: Metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/ZOK 47.5 mg once daily for 12 weeks
Trial: 25994539
Drug: Continuation maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation maintenance therapy with pemetrexed
Trial: 17200357
Drug: Post-vaccine immune
RxNorm normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-vaccine immune response to MART‐1
Trial: 12355941
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy involving intravesical instillation after transurethral resection for superficial bladder cancer
Trial: 9747867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-phenylalanine mustard, 5-fluorouracil, and doxorubicin (PAF)
Trial: 9747867
Drug: L-phenylalanine mustard
RxNorm normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-phenylalanine mustard plus 5-fluorouracil (PF)
Trial: 8010083
Drug: Ofl tablets
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofl tablets evaluated by NONMEM
Trial: 8010083
Drug: Ofl tablets
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofl tablets evaluated by standard approach
Trial: 8010083
Drug: Ofl tablets
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofl tablets evaluated by NONMEM with sparse clinical data
Trial: 27630253
Drug: IncobotulinumtoxinA (IBTA)
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: IncobotulinumtoxinA (IBTA) injection
Trial: 18581096
Drug: Opiate antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Opiate antagonists (nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day)
Trial: 11816482
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg doxorubicin
Trial: 11816482
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg epirubicin
Trial: 9839100
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A (lispro and NPH injected separately)
Trial: 9839100
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B (lispro and NPH mixed in syringe)
Trial: 9839100
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group C (human regular insulin and NPH mixed)
Trial: 2783702
Drug: Amitriptyline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (up to 75 mg/day)
Trial: 2783702
Drug: Alcohol (measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (measured dose)
Trial: 12014128
Drug: Electro-acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture treatment for 4 weeks
Trial: 12014128
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with clinical treatment plus active and/or passive functional exercise
Trial: 29222139
Drug: Losartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (150 mg daily)
Trial: 24965303
Drug: exendin(9-39)NH2 (ex9-39)
RxNorm normalized name: DesPro38Exendin-4(1-39)-Lys6-NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exendin(9-39)NH2 (ex9-39) intravenous infusion
Trial: 24965303
Drug: saline intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline intravenous infusion
Trial: 22364402
Drug: Long-acting methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting methylphenidate formulation (MPH-ret)
Trial: 22364402
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (MPH-IR)
Trial: 20585297
Drug: Very Low-Carbohydrate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very Low-Carbohydrate Diet (VLCD) (<40 g carbohydrate; n=12)
Trial: 16376739
Drug: Type of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type of care at referral (chemotherapy, palliative care, or other supportive care)
Trial: 975978
Drug: 5-percent solution
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-percent solution of metaproterenol sulfate (Alupent)
Trial: 975978
Drug: 0.5-percent solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-percent solution of isoproterenol
Trial: 975978
Drug: metaproterenol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metaproterenol therapy
Trial: 14695785
Drug: Cimetidine (CIM)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (CIM) administered perioperatively, starting 7 days before surgery and continuing for 10 days after surgery.
Trial: 11336170
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha alone (3 MU tiw) or in combination with ribavirin for 6-12 months
Trial: 7956281
Drug: Heparin (6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (6.0 +/- 0.3 IU/kg/hr)
Trial: 7956281
Drug: Both PGI2
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both PGI2 (6.4 +/- 0.3 ng/kg/min) and Heparin (5.0 +/- 0.4 IU/kg/hr)
Trial: 2884759
Drug: Hemodilution (venesection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodilution (venesection and infusion of dextran 40)
Trial: 2884759
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment provided by each center
Trial: 18067517
Drug: COPD training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD training (endurance training at 85% of VO(2max) twice weekly for 7 weeks plus daily home-based training)
Trial: 16689001
Drug: Jiangtang Bushen
RxNorm normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangtang Bushen Recipe (JBR), one dose a day for 4 weeks
Trial: 16689001
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (education course, dietary treatment, and conventional hypoglycemic agent)
Trial: 10720511
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with zidovudine and didanosine with or without nevirapine
Trial: 9178167
Drug: Riluzole 50
RxNorm normalized name: riluzole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole 50 mg daily
Trial: 9178167
Drug: Riluzole 200
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole 200 mg daily
Trial: 8499208
Drug: Propofol (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (total dose 3.2 (SEM 0.3) mg kg‐1 h‐1)
Trial: 8499208
Drug: Flunitrazepam (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (total dose 15 (2) micrograms kg‐1 h‐1)
Trial: 2961355
Drug: Clodronate 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1.6 g/day
Trial: 27923381
Drug: ARTES (parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARTES (parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily)
Trial: 27923381
Drug: QLD (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLD (loading dose of quinine base at 16.6 mg/kg followed 8 h later by an 8-hourly maintenance dose of 8.3 mg/kg quinine base)
Trial: 27923381
Drug: QNLD3 (8.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QNLD3 (8.3 mg/kg quinine base every 8 h)
Trial: 27923381
Drug: QNLD2 (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QNLD2 (12.5 mg/kg quinine base every 12 h)
Trial: 24946021
Drug: Naloxegol 25
RxNorm normalized name: naloxegol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxegol 25 mg oral dose
Trial: 18780882
Drug: Conventional neurodevelopmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional neurodevelopmental theory-based treatment (NDT) (20 sessions in 4 weeks)
Trial: 16029905
Drug: High-dose pergolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pergolide treatment (up to 12 mg/day)
Trial: 9846598
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml cod liver oil daily
Trial: 9846598
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml cod liver oil
Trial: 9846598
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml cod liver oil
Trial: 9846598
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml cod liver oil
Trial: 9846598
Drug: 0 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 ml cod liver oil (control)
Trial: 2679241
Drug: Picotamide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (3 x 300 mg tablets)
Trial: 2679241
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three identical tablets)
Trial: 6249875
Drug: High-dosage antithymocyte
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage antithymocyte globulin (IV regimen)
Trial: 6249875
Drug: Low-dosage antithymocyte
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage antithymocyte globulin (IM regimen)
Trial: 6249875
Drug: No antithymocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithymocyte globulin treatment
Trial: 31498753
Drug: Combined‐modality treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined‐modality treatment (CMT) with 2× ABVD and 20‐Gy involved‐field radiotherapy
Trial: 28289111
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic (flucloxacillin) and topical placebo
Trial: 28289111
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic (fusidic acid) and oral placebo
Trial: 28289111
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral and topical placebos)
Trial: 12355939
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral administration of 5-FU followed by venous injection of MMC
Trial: 8021763
Drug: Clarithromycin, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 15 mg/kg in two divided doses (n = 90)
Trial: 8021763
Drug: Amoxicillin-clavulanate, 40
RxNorm normalized name: Amoxicillin-Clavulanate, 400 mg-57 mg oral tablet, chewable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate, 40 mg/kg in three divided doses (n = 90)
Trial: 8021763
Drug: Amoxicillin-clavulanate (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate (n = 82)
Trial: 31299461
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Treatment (CBT) and Wait-list Control (WLC)
Trial: 25786408
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment in nonremitters after switching
Trial: 21999905
Drug: Treatment Adherence
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Adherence Therapy (TAT)
Trial: 19552746
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg alone
Trial: 19552746
Drug: Anacetrapib 150
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 150 mg co-administered with simvastatin 40 mg
Trial: 11304904
Drug: warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin and bucolome (300 mg once a day)
Trial: 9715781
Drug: Transdermal estradiol-17beta
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol-17beta (E2)
Trial: 7845815
Drug: Steroid-eluting active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-eluting active fixation lead
Trial: 1092617
Drug: Dextran 70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 (Macrodex) - 500 ml at operation and 500 ml on the first postoperative day
Trial: 31107929
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (implants inserted without any augmentation procedures)
Trial: 23608801
Drug: Modified group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified group (paralleled clipping of rectal ligament, 48 patients)
Trial: 19384216
Drug: FFR‐rFVIIa (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR‐rFVIIa (various doses)
Trial: 17479208
Drug: Oral Mg
RxNorm normalized name: cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Mg citrate 300 mg/day (group A)
Trial: 16020987
Drug: Voice therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice therapy techniques
Trial: 9288699
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 daily plus medroxyprogesterone acetate (MPA) 10 mg, days 1-12
Trial: 9288699
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 daily plus MPA 2.5 mg daily
Trial: 9288699
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 daily plus micronized progesterone (MP) 200 mg, days 1-12
Trial: 2852252
Drug: Lisinopril, 20
RxNorm normalized name: Lisinopril, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril, 20 to 80 mg once daily
Trial: 2852252
Drug: Nifedipine retard,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine retard, 20 to 40 mg twice daily
Trial: 18344432
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of blood‐derived circulating progenitor cells (CPCs) (69 +/- 14 x 10(6) CPCs)
Trial: 15800267
Drug: Sunscreen application
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen application (daily application)
Trial: 12055818
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) chemotherapy
Trial: 6360300
Drug: 2000 rad
RxNorm normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 rad in 10 daily fractions
Trial: 24246818
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise as an adjunct smoking cessation treatment
Trial: 20802206
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation ON with medication ON
Trial: 20802206
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation OFF with medication ON
Trial: 20802206
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation ON with medication OFF
Trial: 20802206
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation OFF with medication OFF
Trial: 10782658
Drug: > 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: > 0 and <= 10 g of alcohol/day
Trial: 10782658
Drug: > 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: > 10 and <= 20 g/day
Trial: 10782658
Drug: > 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: > 20 and <= 30 g/day
Trial: 10782658
Drug: > 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: > 30 and <= 40 g/day
Trial: 10782658
Drug: > 40
RxNorm normalized name: Hyrimoz Pediatric Crohn's Starter Kit Patient Weight > 40 KG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: > 40 and <= 50 g/day
Trial: 10782658
Drug: > 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: > 50 g/day
Trial: 8873656
Drug: Accelerated tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated tissue plasminogen activator (TPA) plus intravenous heparin
Trial: 8873656
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and TPA plus intravenous heparin
Trial: 31045669
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block and periarticular injection
Trial: 19047294
Drug: Standard-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose induction chemotherapy (cytarabine, daunorubicin, and 6-thioguanine)
Trial: 19047294
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction chemotherapy (cytarabine and mitoxantrone)